Evaxion A/S
corporate_fare Company Profile
Evaxion A/S (NASDAQ:EVAX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 28 items for EVAX at importance 7 or higher on its 1–10 market-impact scale.
Recent high-impact activity:
- Evaxion Completes Phase 2 Trial Extension for Personalized Cancer Vaccine EVX-01
- Evaxion to Present Novel AI-Based Polio Vaccine Concepts Developed with Gates Foundation
- Evaxion Seeks Shareholder Approval for Highly Dilutive Capital Raise Authorizations
- Evaxion to Present New Phase 2 & Glioblastoma Data at AACR Annual Meeting
- MSD Licenses Evaxion's EVX-B3, Cancer Vaccine EVX-01 Shows Strong Phase 2 Data, Cash Runway to H2 2027
Financial Snapshot
Insider Transactions
EVAX files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.